Amgen 2009 Annual Report Download - page 6
Download and view the complete annual report
Please find page 6 of the 2009 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.-
1 -
2 -
3 -
4 -
5 -
6 -
7 -
8 -
9 -
10 -
11 -
12 -
13 -
14 -
15 -
16 -
17 -
18
-
19
-
20
-
21
-
22
-
23
-
24
-
25
-
26
-
27
-
28
-
29
-
30
-
31
-
32
-
33
-
34
-
35
-
36
-
37
-
38
-
39
-
40
-
41
-
42
-
43
-
44
-
45
-
46
-
47
-
48
-
49
-
50
-
51
-
52
-
53
-
54
-
55
-
56
-
57
-
58
-
59
-
60
-
61
-
62
-
63
-
64
-
65
-
66
-
67
-
68
-
69
-
70
-
71
-
72
-
73
-
74
-
75
-
76
-
77
-
78
-
79
-
80
-
81
-
82
-
83
-
84
-
85
-
86
-
87
-
88
-
89
-
90
-
91
-
92
-
93
-
94
-
95
-
96
-
97
-
98
-
99
-
100
-
101
-
102
-
103
-
104
-
105
-
106
-
107
-
108
-
109
-
110
-
111
-
112
-
113
-
114
-
115
-
116
-
117
-
118
-
119
-
120
-
121
-
122
-
123
-
124
-
125
-
126
-
127
-
128
-
129
-
130
-
131
-
132
-
133
-
134
-
135
-
136
-
137
-
138
-
139
-
140
-
141
-
142
-
143
-
144
-
145
-
146
-
147
-
148
-
149
-
150
-
151
-
152
-
153
-
154
-
155
-
156
-
157
-
158
-
159
-
160
-
161
-
162
-
163
-
164
-
165
-
166
-
167
-
168
-
169
-
170
-
171
-
172
-
173
-
174
-
175
-
176
-
177
-
178
-
179
-
180
 |
 |
This chart shows selected product candidates in Amgen’s development pipeline. For more information on our pipeline, visit www.amgen.com or refer to Amgen’s most recent Form 10-K, included as
part of this publication. For important safety information about Amgen’s approved, marketed, or commercially available medicines, visit www.amgen.com for links to the product websites. This table is
as of February 5, 2010, and shows the status of selected clinical programs and molecules in Amgen’s product pipeline. Amgen’s product pipeline will change over time as programs and molecules move
through the drug development process, including progressing to market or failing in clinical trials, due to the nature of the development process.
Amgen’s Pipeline —
Advancing Science to Serve Patients
Phase 1
AMG 145
Hypercholesterolemia
AMG 151
Type 2 diabetes
AMG 157
Asthma
AMG 167
Bone-related conditions
AMG 191
Infl ammatory diseases
AMG 208
Various cancer types
AMG 221
Type 2 diabetes
AMG 557
Systemic lupus erythematosus
AMG 745
Muscle-wasting disorders
AMG 747
Neuroscience
AMG 761
Asthma
AMG 811
Systemic lupus erythematosus
AMG 820
Various cancer types
AMG 888
Various cancer types
AMG 900
Various cancer types
Phase 2
AMG 102
Various cancer types
AMG 108
Rheumatoid arthritis
AMG 222
Type 2 diabetes
AMG 223
Hyperphosphatemia
AMG 386
Various cancer types
AMG 479
Various cancer types
AMG 785
Bone-related conditions, including
postmenopausal osteoporosis
and fracture healing
AMG 827
Infl ammatory diseases
AMG 853
Asthma
Conatumumab (AMG 655)
Various cancer types
Denosumab
Rheumatoid arthritis
Dulanermin (rhApo2L/TRAIL)
Various cancer types
Motesanib
First-line breast cancer
Omecamtiv mecarbil (AMG 423)
Heart failure
Panitumumab
Locally advanced head
and neck cancer
Romiplostim
Chemotherapy-induced
thrombocytopenia
Romiplostim
Myelodysplastic syndromes
Phase 3
Cinacalcet
Cardiovascular disease in patients
with secondary hyperparathyroidism
and chronic kidney disease under-
going maintenance dialysis
Darbepoetin alfa
Anemia in heart failure
Denosumab
Bone loss induced by hormone
ablation therapy in breast cancer
or prostate cancer
Denosumab
Cancer-related bone damage
(skeletal-related events) from
advanced malignancies in breast
cancer, prostate cancer, and solid
tumors including multiple myeloma
Denosumab
Male osteoporosis
Denosumab
Postmenopausal osteoporosis
Denosumab
Prevention of bone metastases in
breast cancer
Denosumab
Prevention of bone metastases in
prostate cancer
Motesanib
First-line non-small cell lung cancer
Panitumumab
First- and second-line colorectal
cancer
Panitumumab
Metastatic and/or recurrent head
and neck cancer